Abstract: Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof.
Type:
Application
Filed:
August 4, 2010
Publication date:
June 14, 2012
Applicant:
The Government of the USA, as Represented by the Secretary, Dept. of Health and Human Services, CDC
Inventors:
Larry J. Anderson, Lia M. Haynes, Ralph A. Tripp